2024年全球新药研发趋势

AC T I V I T Y, PRODUC T I V I T Y, AND ENABLER S Introduction Biomedical advances are transforming healthcare globally. The multi-stakeholderecosystem that enables this progress has been buffeted by the global COVID-19pandemic and is resetting and refocusing on future opportunities to advancethe understanding of human biology and disease, discover and develop newtherapeutics, and provide evidence of the clinical value of these innovations — forindividual patients, populations, and health systems. By all of the traditional metrics,including funding levels, numbers of trial starts, drug launches, R&D success rates,and many others, it is clear that industry and investors continue to see tremendousvalue in the vast array of ongoing research programs around the world. This report assesses the trends in new drug launchesand the overall number of initiated clinical trials. It alsoprofiles the state of R&D funding and the activity ofcompanies of different types. The results of research arecompared to the input effort in a Clinical DevelopmentProductivity Index. The notable acceleration andadaptability of the innovation ecosystem is examined interms of several enablers of R&D productivity, includingthe relationship between shortening trial durationsand the ‘white space’ within clinical developmenttimelines that have been reducing for some diseases andincreasing for others. The contributions to this report from Mohit Agarwal,Taskin Ahmed, Chris Bamford, Vaibhav Bhalotia, TanyaBhardwaj, Lucy Haggerty, Julia Kern, BhagyashreeNawar, Urvashi Porwal, Tanushree Thakur, and dozens ofothers at IQVIA are gratefully acknowledged. Find Out More If you wish to receive future reports from the IQVIAInstitute for Human Data Science or join our mailing list,visit iqviainstitute.org. MURRAY AITKENExecutive DirectorIQVIA Institute for Human Data Science The research included in this report was undertakenindependently by the IQVIA Institute for HumanData Science as a public service, without industry orgovernment funding. The analytics in this report arebased on proprietary IQVIA databases and/or third-party information and are not derived from proprietarysponsor trial information. REFERENCING THIS REPORT Please use this format when referencing content from this report:Source: IQVIA Institute for Human Data Science. Global Trends in R&D 2024: Activity, Productivity, and Enablers. February 2024.Available from www.iqviainstitute.org ©2024 IQVIA and its affiliates. All reproduction rights, quotations, broadcasting, publications reserved. No part of this publication may be reproduced ortransmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, withoutexpress written consent of IQVIA and the IQVIA Institute. Global Trends in R&D 2024: Activity, Productivity, and Enablers Overview2R&D funding4Clinical trial activity12New drug approvals and launches29Clinical development productivity40Productivity enablers58Notes on sources73Methodologies74References75About the authors76About the Institute78 Overview grown 5%. CAR T-cell therapy clinical research is focusedon oncology, while other diseases may benefit from othercell and gene modalities. R&D FUNDING R&D funding levels have rebounded in 2023 after a steepdecline from the peak seen in 2020-21. While the numberof deals has fallen, high profile and high value dealsindicate robust interest from investors and innovatorsin the next generation of therapies. Biopharma fundinglevels rebounded to $72Bn in 2023, up from $61Bn in2022, although still well below the levels in 2020-21.M&A activity jumped to $140Bn from $78Bn in 2022,while median deal value dipped for the second year. Theleading deal and M&A activity areas related to antibodydrug conjugates accounted for 47% of disclosed M&Adeals valued over $2Bn and 85% of large oncologydeals. Deals involving China-based companies remainedsignificant and AI deals more than doubled. R&Dexpenditure reported by large pharma corporationstotaled a record $161Bn in 2023, an increase of almost50% since 2018, and historically high at 23.4% of netsales for those companies. Obesity clinical trials in 2023 were up 68% from 2022and have nearly doubled when compared to five yearsago, including 124 drugs in active development, 40% ofwhich are GIP/GLP glucagon receptor agonists and 46% ofwhich have oral formulations in development. Neurologyresearch is focused on Alzheimer’s, Parkinson’s, andepilepsy, with a range of other often rare diseases.Depression trial starts were 25% lower in 2023 thanpre-pandemic with psychedelics being tested in nearly40% of the 2023 trial starts. Infectious disease trialsslowed to below pre-pandemic levels from both COVID-19trials and other infection targets, and a significantreduction in trials starts for antibacterials. NEW DRUG APPROVALS AND LAUNCHES A total of 69 novel active substances (NASs) werelaunched globally in 2023, up six from